[go: up one dir, main page]

WO2002038792A3 - Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih) - Google Patents

Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih) Download PDF

Info

Publication number
WO2002038792A3
WO2002038792A3 PCT/FR2001/003512 FR0103512W WO0238792A3 WO 2002038792 A3 WO2002038792 A3 WO 2002038792A3 FR 0103512 W FR0103512 W FR 0103512W WO 0238792 A3 WO0238792 A3 WO 0238792A3
Authority
WO
WIPO (PCT)
Prior art keywords
human immunodeficiency
analysing
hiv
immunodeficiency virus
novel method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2001/003512
Other languages
English (en)
Other versions
WO2002038792A2 (fr
Inventor
Francois Clavel
Fabrizio Mammano
Esther Race
Elisabeth Dam
Veronique Obry
Virginie Trouplin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Bioalliance Pharma SA
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Bioalliance Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0014495A external-priority patent/FR2816634A1/fr
Priority claimed from FR0103970A external-priority patent/FR2816635A1/fr
Priority to CA002429073A priority Critical patent/CA2429073A1/fr
Priority to AU2002223052A priority patent/AU2002223052B2/en
Priority to AU2305202A priority patent/AU2305202A/xx
Priority to EP01993700A priority patent/EP1364071A2/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Bioalliance Pharma SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to JP2002542106A priority patent/JP2005500003A/ja
Priority to IL15578001A priority patent/IL155780A0/xx
Publication of WO2002038792A2 publication Critical patent/WO2002038792A2/fr
Anticipated expiration legal-status Critical
Priority to US10/435,659 priority patent/US20070269797A9/en
Publication of WO2002038792A3 publication Critical patent/WO2002038792A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode d'analyse des caractéristiques phénotypiques présentées par certaines souches de virus, notamment les virus de l'immunodéficience humaine, mettant en oeuvre la construction d'un virus recombinant obtenu par recombinaison homologue. La présente invention concerne également un kit comprenant les amorces, les vecteurs, les hôtes cellulaires, les produits et réactifs nécessaires pour réaliser une amplification par PCR, et les produits et réactifs permettant la détection d'un marqueur, pour la mise en oeuvre de la méthode de l'invention.
PCT/FR2001/003512 2000-11-10 2001-11-09 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih) Ceased WO2002038792A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IL15578001A IL155780A0 (en) 2000-11-10 2001-11-09 Novel method for analysing phenotypic characteristics of human imunodeficiency virus (hiv)
JP2002542106A JP2005500003A (ja) 2000-11-10 2001-11-09 ヒト免疫不全ウイルス（ｈｉｖ）の表現型特性の新規な分析法
AU2002223052A AU2002223052B2 (en) 2000-11-10 2001-11-09 Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV)
AU2305202A AU2305202A (en) 2000-11-10 2001-11-09 Novel method for analysing phenotypic characteristics of human immunodeficiency virus (hiv)
EP01993700A EP1364071A2 (fr) 2000-11-10 2001-11-09 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih)
CA002429073A CA2429073A1 (fr) 2000-11-10 2001-11-09 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih)
US10/435,659 US20070269797A9 (en) 2000-11-10 2003-05-12 Method for analysis of the phenotypic characteristics of the human immunodeficiency virus (HIV)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR0014495A FR2816634A1 (fr) 2000-11-10 2000-11-10 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih)
FR00/14495 2000-11-10
FR01/03970 2001-03-23
FR0103970A FR2816635A1 (fr) 2000-11-10 2001-03-23 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih)
US09/817,135 2001-03-27
US09/817,135 US20020123036A1 (en) 2000-11-10 2001-03-27 Method for analysing human immunodeficiency virus (HIV) phenotypic characteristics

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/817,135 Continuation-In-Part US20020123036A1 (en) 2000-11-10 2001-03-27 Method for analysing human immunodeficiency virus (HIV) phenotypic characteristics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/435,659 Continuation US20070269797A9 (en) 2000-11-10 2003-05-12 Method for analysis of the phenotypic characteristics of the human immunodeficiency virus (HIV)

Publications (2)

Publication Number Publication Date
WO2002038792A2 WO2002038792A2 (fr) 2002-05-16
WO2002038792A3 true WO2002038792A3 (fr) 2003-09-25

Family

ID=27248715

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/003512 Ceased WO2002038792A2 (fr) 2000-11-10 2001-11-09 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih)

Country Status (7)

Country Link
US (2) US20030207294A1 (fr)
EP (1) EP1364071A2 (fr)
JP (2) JP2005500003A (fr)
AU (2) AU2305202A (fr)
CA (1) CA2429073A1 (fr)
IL (1) IL155780A0 (fr)
WO (1) WO2002038792A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546076B2 (en) 2007-05-25 2013-10-01 Tibotec Pharmaceuticals Ltd. Mutational profile in HIV-1 GAG cleavage site correlated with phenotypic drug resistance

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246859T3 (es) 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
AU2002226316B2 (en) 2000-10-20 2008-06-26 Virco Bvba Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
FR2829503B1 (fr) * 2001-03-23 2007-06-01 Bioalliance Pharma Nouvelee methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)
FR2829502B1 (fr) * 2001-03-23 2006-01-13 Bioalliance Pharma Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)
FR2829501B1 (fr) * 2001-03-23 2006-03-03 Bioalliance Pharma Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)
US7306901B2 (en) * 2001-08-08 2007-12-11 Tibotec Pharmaceuticals, Ltd. Methods and means for assessing HIV envelope inhibitor therapy
ATE389029T1 (de) 2001-11-08 2008-03-15 Tibotec Pharm Ltd Protease assay zur kontrolle medikamentöser therapie
US7217506B2 (en) 2002-07-01 2007-05-15 Tibotec Pharmaceuticals, Ltd. Mutational profiles in HIV-1 protease correlated with phenotypic protease inhibitor resistance
WO2004003223A2 (fr) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Nouveaux profils mutationnels dans une transcriptase inverse du vih-1 correles a une resistance phenotypique aux medicaments
WO2004003513A2 (fr) * 2002-07-01 2004-01-08 Virologic, Inc. Compositions et methodes permettant de mesurer la capacite de replication d'un virus pathogene
EP1914309A1 (fr) * 2006-10-20 2008-04-23 Eurofins Viralliance Inc. Méthode pour l'essai du tropisme d'HIV du CCR5 et/ou CXCR4 co-répéteur et/ou la sensibilité d'inhibiteur d'entrée
WO2008047227A2 (fr) * 2006-10-20 2008-04-24 Eurofins Viralliance Inc. Procédé d'analyse du tropisme du vih-1 pour les co-récepteurs ccr5 et/ou cxcr4, et/ou sensibilité à des inhibiteurs d'entrée
WO2014145408A1 (fr) * 2013-03-15 2014-09-18 The Johns Hopkins University Méthodes cliniques permettant de déterminer le tropisme de récepteur vih-1 et les réservoirs cellulaires de la réplication du vih-1
WO2020150499A1 (fr) * 2019-01-16 2020-07-23 Fred Hutchinson Cancer Research Center Méthodes pour marquer et isoler des cellules infectées par le virus de l'immunodéficience humaine
CN115287372A (zh) * 2022-04-21 2022-11-04 中国人民解放军军事科学院军事医学研究院 扩增hiv-1 rre全长序列的引物组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6103462A (en) * 1998-05-29 2000-08-15 Institut Pasteur Rapid single-cycle assay for human immunodeficiency virus type-1 drug resistance
WO2000066774A2 (fr) * 1999-04-28 2000-11-09 Glaxo Group Limited Analyse amelioree et ses reactifs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033992A1 (fr) * 1997-12-31 1999-07-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Elements de transport constitutifs d'une particule intracisternale murine type a et utilisation de ces elements

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6103462A (en) * 1998-05-29 2000-08-15 Institut Pasteur Rapid single-cycle assay for human immunodeficiency virus type-1 drug resistance
WO2000066774A2 (fr) * 1999-04-28 2000-11-09 Glaxo Group Limited Analyse amelioree et ses reactifs

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
HEILEK-SNYDER G M ET AL: "Measuring HIV-1 integrase inhibitor susceptibility using a recombinant virus-based, single cycle replication assay.", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND, vol. 40, 2000, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy;Toronto, Ontario, Canada; September 17-20, 2000, 2000, pages 300, XP001025652 *
HERTOGS K ET AL: "A RAPID METHOD FOR SIMULTANEOUS DETECTION OF PHENOTYPIC RESISTANCE TO INHIBITORS OF PROTEASE AND REVERSE TRANSCRIPTASE IN RECOMBINANT HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ISOLATES FROM FROM PATIENTS TREATED WITH ANTIRETROVIRAL DRUGS", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 42, no. 2, February 1998 (1998-02-01), pages 269 - 278, XP000946883, ISSN: 0066-4804 *
KELLAM P ET AL: "RECOMBINANT VIRUS ASSAY: A RAPID, PHENOTYPIC ASSAY FOR ASSESSMENT OF DRUG SUSCEPTIBILITY OF HUMAN IMMUNODEFIENCY VIRUS TYPE 1 ISOLATES", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 38, no. 1, January 1994 (1994-01-01), pages 23 - 30, XP000952459, ISSN: 0066-4804 *
LIN PIN-FANG ET AL: "Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 40, no. 1, 1996, pages 133 - 138, XP001016383, ISSN: 0066-4804 *
MARTINEZ-PICADO J ET AL: "ANTIRETROVIRAL RESISTANCE TESTING. HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CLONING VECTORS FOR", JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 37, no. 9, September 1999 (1999-09-01), pages 2943 - 2951, XP000886935, ISSN: 0095-1137 *
MASQUELIER BERNARD ET AL: "Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): Multicenter study of patients treated with RT inhibitors.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 45, no. 6, June 2001 (2001-06-01), pages 1836 - 1842, XP001016398, ISSN: 0066-4804 *
RACE ESTHER ET AL: "Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.", AIDS (HAGERSTOWN), vol. 13, no. 15, 22 October 1999 (1999-10-22), pages 2061 - 2068, XP001016325, ISSN: 0269-9370 *
ROBINSON LAURENCE H ET AL: "HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays.", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 16, no. 12, 10 August 2000 (2000-08-10), pages 1149 - 1156, XP002183817, ISSN: 0889-2229 *
SCARLATTI GABRIELLA ET AL: "In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.", NATURE MEDICINE, vol. 3, no. 11, November 1997 (1997-11-01), pages 1259 - 1265, XP001024255, ISSN: 1078-8956 *
TROUPLIN VIRGINIE ET AL: "Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using as recombinant phenotypic assay.", JOURNAL OF VIROLOGY, vol. 75, no. 1, January 2001 (2001-01-01), pages 251 - 259, XP002183818, ISSN: 0022-538X *
WILLEY ET AL: "Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 68, no. 7, July 1994 (1994-07-01), pages 4409 - 4419, XP002119922, ISSN: 0022-538X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546076B2 (en) 2007-05-25 2013-10-01 Tibotec Pharmaceuticals Ltd. Mutational profile in HIV-1 GAG cleavage site correlated with phenotypic drug resistance

Also Published As

Publication number Publication date
JP2008022861A (ja) 2008-02-07
EP1364071A2 (fr) 2003-11-26
US20030207294A1 (en) 2003-11-06
JP2005500003A (ja) 2005-01-06
AU2305202A (en) 2002-05-21
IL155780A0 (en) 2003-12-23
CA2429073A1 (fr) 2002-05-16
WO2002038792A2 (fr) 2002-05-16
AU2002223052B2 (en) 2007-09-20
US20040053219A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
WO2002038792A3 (fr) Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih)
WO2003068923A3 (fr) Signal d'incorporation de vecteurs de virus de la grippe
WO2005034992A3 (fr) Mecanismes pour ameliorer l'etendue de la reponse immunitaire de brins et de variantes differentes de vih
GB2405406B (en) Viral vectors
WO2001044286A3 (fr) Proteine a cinq helices
SI1427817T1 (sl) Razmnoževanje virusov in celičnih kultur
WO2001075087A3 (fr) Variantes de lasubtilisine
WO2004094466A3 (fr) Virus codant une proteine membranaire mutante
WO2004072097A3 (fr) Systeme base sur une puce pour le diagnostic du vih
WO2002004007A3 (fr) Formes (fixes) stables de proteines virales capsidiales et de proteines virales capsidiales hybrides, de preference les proteines l1 du papillomavirus, et leurs utilisations
WO2002027007A3 (fr) Production de vecteurs viraux
AU5322800A (en) Cloned genone of infectious hepatitis c virus of genotype 2a and uses thereof
WO2004044182A3 (fr) Lignees cellulaires hautement permissives pour replication de l'arn du virus de l'hepatite c
WO2005001029A3 (fr) Virus ancestraux et vaccins
WO2002022663A3 (fr) Retrovirus resistant au stress
AU2003247651A1 (en) PREPARATION OF STEREOISOMERS OF (3ALPHA, 3ALPHA/BETA, 6ALPHA/BETA) HEXAHYDROFURO(2,3-b)FURAN-3-OL
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
WO2005110492A3 (fr) Méthode pour utiliser les vecteurs adénovirals amener une réponse immunitaire
WO2001057245A3 (fr) Test de resistance au vih-1
WO2005108606A3 (fr) Methode d’etude de la variabilite genique et fonctionnelle du vih et kit pour sa mise en oeuvre
WO2002027027A8 (fr) Criblage de substances therapeutiques en rapport avec des maladies infectieuses
AU2001249928A1 (en) Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv
WO2003046213A3 (fr) Procede pour concentrer et identifier des vih
WO2002004595A3 (fr) Production de papillomavirus humain chimerique
WO2007018550A3 (fr) Compositions et methodes pour detecter une infection par le vih-1/vih-2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 155780

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002542106

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2429073

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10435659

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001993700

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002223052

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001993700

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10435659

Country of ref document: US